1

2 3 4 5 IN THE UNITED STATES DISTRICT COURT 6 FOR THE DISTRICT OF ARIZONA 7 8 Richard Di Donato, Individually and On Behalf of all Others Similarly Situated, No. CV-16-00302-PHX-NVW 9 ORDER 10 Plaintiff, 11 v. 12 Insys Therapeutics, Inc.; et al., 13 Defendants. 14 15 Before the Court is Plaintiff's Motion for Preliminary Approval of Settlement with 16 Defendant Baker. (Doc. 341.) The Motion omits information necessary or helpful to 17 whether to grant preliminary or final approval, including: 18 1. The quantum of class damages is not stated or even estimated, even if disputed 19 between the parties. 20 2. The quantum of recovery to the class as a whole and as a proportion of claimed 21 damages per shareholder is not stated, only the recovery per share if all class 22 members apply. 23 3. The source of funding of the \$2,000,000 settlement amount is not stated. Is it 24 from Defendant Baker's personal resources? Is it partly or entirely from 25 insurance resources? If from insurance resources, what are the nature and 26 amounts of such policies and coverages? What are the limits in coverage 27 amounts of each insurance source? How much of the total available insurance 28

Case 2:16-cv-00302-NVW Document 342 Filed 05/26/20 Page 2 of 2

1	coverage would be expended to fund the Settlement? What insurance coverage
2	would remain for the benefit of the non-settling defendants?
3	These data are surely within the knowledge or estimate of the parties and should
4	have been stated in the Motion and in the proposed class disclosure.
5	IT IS THEREFORE ORDERED that the settling parties file by June 9, 2020, a
6	Supplement to Plaintiff's Motion for Preliminary Approval of Settlement with Defendant
7	Baker (Doc. 341) giving the foregoing information.
8	Dated: May 26, 2020.
9	NeilVWsko
10	Neil V. Wake
11	Senior United States District Judge
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	